Transcription factor combination for Type 1 Diabetes (MOG3) (MOG3)

MOG3 refers to a proprietary combination of transcription factors identified through the Mogrify platform, designed to facilitate the direct in vivo reprogramming of cells into functional insulin-producing cells for the treatment of Type 1 Diabetes (Mogrify, 2026). The Mogrify technology employs a data-driven computational framework to predict the minimal set of regulatory factors needed to drive cell identity conversion, bypassing the need for induced pluripotent stem cells (Rackham et al., 2016). In the MOG3 program, these factors are intended to transform a patient's own cells, such as exocrine pancreatic cells, into beta-like cells capable of sensing glucose and secreting insulin (Mogrify, 2026). This therapeutic strategy aims to provide a sustainable, endogenous source of insulin, potentially eliminating the need for external insulin injections and improving long-term outcomes for diabetic patients. The combination works by activating the master regulatory networks that define beta cell identity and function, thereby restoring metabolic homeostasis. This approach represents a novel frontier in regenerative medicine, focusing on the direct conversion of cell types within the body to treat chronic metabolic diseases.

Other names

Mogrify MOG3Type 1 Diabetes reprogramming cocktailPancreatic beta cell conversion factors

Direct cellular reprogramming (transdifferentiation) of source cells into functional insulin-producing pancreatic beta-like cells to restore endogenous insulin secretion.